Multimorbidity in older patients creates a challenge because you're dealing with multiple diseases and multiple medications, explained Michael Steinman, MD, professor of medicine, University of California, San Diego.
Multimorbidity in older patients creates a challenge because you're dealing with multiple diseases and multiple medications, explained Michael Steinman, MD, professor of medicine, University of California, San Diego.
Transcript
Why are medication management strategies particularly important for older patients?
One of the issues with older patients is the presence of multimorbidity, so the challenge has become that much more complex because we’re not just dealing with a single disease, were dealing with multiple diseases and thinking about the interaction of all of those diseases, including the multiple medications a patient may be taking. They might make sense for one disease at a time, but when you add up all of the diseases and a patient ends up taking 18 medications, 9 of which are interacting with each other, and the patient can’t pay for their electric bill because they’re spending all their money on medications, that’s a problem.
So, being attentive the unique needs that arise from the presence of multimorbidity and thinking holistically about the patient and how to optimize their medication regimen in a way that makes sense for the person, not just the individual disease, is critical.
Are there challenges with trying to reach and engage these patients?
I think there’s a lot of variability in what strategies work for different patients. For example, if a strategy is just focused on getting patients to remember to take their medications more, that could be really useful for patients whose primary problem is just they forget to take their medications and having improved strategies for helping them, for example, with medication organizers or reminders. But, just to build on that example, a lot of nonadherence isn’t due to forgetting, it’s due to patients not thinking their medication is useful, not understanding why they’re taking it, or having real or perceived side effects and not wanting to take the medicine as a result.
Again, we need to be patient-centered on how we approach these things and really understanding what’s going on in the patient’s mind, why they’re acting or not acting a certain why, what’s going on in the prescriber’s mind, why they’re acting or not acting in a certain way, and addressing those levers accordingly.
Cellular Therapies in Lymphoma Bring Hope, but Optimizing Their Use Remains a Challenge
December 10th 2023Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More